Compare Unilever plc (UL) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Unilever plc vs Zimmer Biomet Holdings Inc — how do they compare? Unilever plc trades at $61.66 (market cap $131.63B), while Zimmer Biomet Holdings Inc trades at $88.9 (market cap $16.95B). The key difference: Unilever plc is far larger — about 7.8× Zimmer Biomet Holdings Inc's market cap, and Unilever plc pays the higher dividend (3.43%). Which is the better fit depends on your goals — on Pluang, investors hold Unilever plc for 112 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| UL | ZBH | |
|---|---|---|
Market Cap | $131.63B | $16.95B |
Volume | 2,978,741 | 2,505,240 |
Sector | Consumer Staples | Health |
52-Week High | $74.59 | $103.98 |
52-Week Low | $55.05 | $79.58 |
Typical Hold Time | 112 Days | 89 Days |
Enterprise Value | $156.65B | $24.02B |
Dividend Yield | 3.43% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Unilever (UL) trades at $60.98, up 0.3% on the day, amid a bearish technical outlook and mixed financial performance. Revenue declined to $50.50 billion in 2025, though net income improved to $9.47 billion, with a high net margin of 18.74%. Recent earnings have consistently missed expectations, while the company is streamlining its portfolio through a planned food business merger with McCormick, facing regulatory scrutiny.
The stock presents a cautious outlook with strong profitability metrics like a 54.56% ROE offset by valuation concerns (P/E of 21.59) and earnings misses. Risks include integration challenges from the McCormick deal and competitive pressures, but its focus on beauty and personal care offers growth potential in emerging markets.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal despite recent earnings beats. The company shows steady revenue growth to $8.23B in 2025, though net margins have compressed from 13.84% in 2023 to 8.56%. Analyst consensus is mixed with 40% buy ratings but a $103.11 price target suggesting 16.5% upside. Recent news highlights dividend declarations and leadership promotions aimed at accelerating commercial transformation.
ZBH presents a value opportunity with reasonable valuation multiples (P/E 21.48, P/S 2.04) and consistent earnings outperformance, but faces headwinds from margin pressure and technical weakness. The stock's investment case hinges on execution of growth initiatives amid competitive and debt-related risks, with current levels offering entry near support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Unilever plc
Unilever is a diversified personal product (42% of 2021 sales by value), home care (20%), and packaged food (38%) company. Its brands include Knorr soups and sauces, Hellmann's mayonnaise, Lipton teas, Axe and Dove skin products, and the TRESemme haircare brand. The firm has been acquisitive in recent years
Read more on UL →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
